B. Riley Securities analyst Alex Rygiel maintains Beazer Homes USA (NYSE:BZH) with a Buy and raises the price target from $18 to $20.
Roth Capital Downgrades Catalyst Pharmaceuticals to Neutral, Raises Price Target to $15.5
Roth Capital analyst Scott Henry downgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) from Buy to Neutral and raises the price target from $10 to $15.5.